 |
|
|
|
 |
|
|
| Article 1 to 10 out of 12 concerning Solvay SA
|
-
Abbott to Acquire Solvay Pharmaceuticals Business
(01 Oct 2009)
Diversifies Abbott's pharmaceutical products, expanding international growth platform
Abbott announced a definitive agreement with the Solvay Group for Abbott to acquire Solvay's pharmaceuticals business for EUR 4.5 billion(US$6.6 billion) in cash, providing Abbott with a large and complementary portfolio of pharmaceutical products ...
-
MediGene Signs Agreement with Solvay for the Commercialization of Veregen in Germany, Austria, and Switzerland
(30 Sep 2009)
MediGene AG has signed a license and supply agreement with Solvay Arzneimittel GmbH, the German affiliate of Solvay Pharmaceuticals (Solvay) for the supply and commercialization of VeregenŽ (formerly Polyphenon EŽ ointment) in Germany, Austria, and ...
-
Solvay Group holds 93.1% of Innogenetics shares
(20 Oct 2008)
Offer on Innogenetics shares is extended from 22 October to 12 November
Solvay Pharmaceuticals S.A., a subsidiary of the Solvay Group announced that it will acquire 2,714,371 additional shares of Innogenetics N.V. in a cash transaction valued at EUR 6.5 per share, representing EUR 200.7 million for 100% of the ...
-
Solvay Pharmaceuticals acquires Innogenetics
(11 Sep 2008)
Solvay Group holds 84.3% of Innogenetics shares
Solvay Pharmaceuticals S.A., a subsidiary of the Solvay Group, announced that it succeeded to acquire Innogenetics N.V. in a cash transaction valued at EUR 6.5 per share, representing EUR 200.7 million for 100% of the Innogenetics shares. The offer ...
-
Solvay Pharmaceuticals S.A. launches friendly bid to acquire Innogenetics
(29 Apr 2008)
Building on a successful R&D co-operation
Solvay Pharmaceuticals S.A., a subsidiary of Solvay, and Innogenetics N.V. jointly announced that Solvay Pharmaceuticals S.A. will make a conditional tender offer to acquire Innogenetics in a cash transaction valued at EUR 5.75 per share.Solvay ...
-
Innogenetics and Solvay Pharmaceuticals extend collaboration for biomarker discovery
(10 Apr 2008)
Innogenetics announced a 2-year extension of its longstanding research collaboration with Solvay Pharmaceuticals. Since November 1997, Solvay and Innogenetics have collaborated on a joint research program to explore new targets for Solvay's drug ...
-
Bionas Signs Service Contract with Solvay Pharmaceuticals
(02 Oct 2007)
Bionas GmbH announced that it has signed a service contract with Solvay Pharmaceuticals GmbH. The contract covers the metabolic profiling of several drug candidates identified in the context of Solvay´s obesity research program. Financial details ...
-
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals announce receipt of an FDA action letter for bifeprunox
(14 Aug 2007)
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth, announced the receipt of an action letter from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for bifeprunox, an atypical ...
-
Solvay's SLV 319 obesity candidate treatment advances in phase II clinical trials
(13 Dec 2006)
Triggering a milestone payment from co-development and co-commercialization partner Bristol-Myers Squibb
Solvay announced that a phase IIB study has started following a decision of the joint development committee for SLV319, which moved this obesity treatment candidate into further phase II clinical trials.SLV319 belongs to a novel class of agents ...
-
Bionas cell profiling device selected by Solvay Pharmaceuticals for Target Validation
(10 Nov 2006)
Bionas GmbH and Solvay Pharmaceuticals Research Laboratories announce that the Bionas(R) 2500 analyzing system has been recognized to be a valuable tool for target validation studies."It is known that angiotensin 1-8 (angiotensin II) acts via two ...
|
|
|
|
|
Top